Illumina (NASDAQ:ILMN) Issues Q4 Earnings Guidance

Illumina (NASDAQ:ILMN) updated its fourth quarter earnings guidance on Tuesday. The company provided earnings per share guidance of $0.91-$0.93 for the period, compared to the consensus earnings per share estimate of $0.92. The company issued revenue guidance of $1.10 billion, compared to the consensus revenue estimate of $1.07 billion.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Barclays upped their target price on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Piper Sandler lowered their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research note on Thursday, October 17th. JPMorgan Chase & Co. boosted their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Morgan Stanley lowered their target price on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a report on Monday. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $165.63.

Illumina Price Performance

Illumina stock opened at $144.22 on Tuesday. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The stock’s 50 day moving average is $140.92 and its 200-day moving average is $132.88. Illumina has a 12 month low of $100.08 and a 12 month high of $156.66. The company has a market capitalization of $22.87 billion, a price-to-earnings ratio of -14.48 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the prior year, the business posted $0.33 EPS. The business’s revenue was down 3.5% compared to the same quarter last year. Equities research analysts expect that Illumina will post 4.11 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.